Marvel Biosciences Corp · TSXV:MRVL
Marvel Biosciences — Investor Presentation (May 2023)
29 slides from Marvel Biosciences's investor presentation, May 2023
Slide 1: Corporate Presentation – May 2023
Corporate Presentation – May 2023 MRVL - TSXV www.marvelbiotechnology.com
Slide 2: Disclaimer
Disclaimer This corporate presentation and the information contained herein (the “Presentation”) is proprietary and for authorized use only. It is being provided for the use of prospective investors with the express understanding that, without the prior permission in writing from Marvel Biosciences
Slide 3: Marvel's Target Markets: Alzheimer's Disease and Depression
Marvel’s Target Markets Alzheimer’s Disease and Depression
Slide 4: Epidemic of Alzheimer's Disease
Epidemic of Alzheimer’s Disease - AS Dementia Incidence by Age Shift in the Global Demographic e (1980 2000 [] 2050 | 2100 f + Memory loss disrupts daily life onl 2 2 PREDR Challenge with completing tasks e and concentration. “= hit Become confused, anxious, Tt ii Alzheimer’s Disease Problems speaki
Slide 5: Two Big Markets: Alzheimer's Disease and Depression
Two Big Markets: Alzheimer’s Disease and Depression Alzheimer’s Depression Successfully Redeveloped Drugs One in Ten persons over 65 affected2 One in Eight adults takes an anti-depressant3 $320B in US alone on care in 2022 $326B in US alone for economic burden4 Few treatment options Up to 40% of AD
Slide 6: Two Major Events in Neuroscience in 2022
Two Major Events in Neuroscience in 2022 Alzheimer’s Depression Successfully Redeveloped Drugs Renewed interest in Alzheimer’s and Renewed interest in new anti-depressants Dementia Source: https://www.nature.com/articles/s41380-022-01661-0 6
Slide 7: The Need for a Novel Approach to New Anti-Depressants
The Need for a Novel Approach to New Anti-Depressants Selective Serotonin Reuptake Inhibitors (SSRIs) are the most prescribed anti-depressant drugs (e.g. Prozac) 2-4 UP TO UP TO Weeks LENGTH OF TIME FOR 30% PATIENTS STOP TREATMENT 40% PATIENTS EXPERIENCING SSRI TO WORK APATHY / LOSS OF MOTIVATION A
Slide 8: Redeveloping Known Drugs to Target New Diseases
Redeveloping Known Drugs to Target New Diseases 50+ 2 2 40B YEARS EXPERIENCE PROVEN PROPRIETARY DISEASE AREAS TOTAL MARKET COMPOUNDS VALUE
Slide 9: Redevelopment of Off Patented Drugs: De-Risking the Science
Redevelopment of Off Patented Drugs: De-Risking the Science Successfully Redeveloped Drugs De-Risk Drug Development Thalidomide to Revlimid (>$1.3B in sales) • Modify an existing drug to improve functionality morning sickness cancer • Use the new drug to target Cyclosporin to Voclosporin (>$2B mkt c
Slide 10: Marvel is Redeveloping Istradefylline
Marvel is Redeveloping Istradefylline Istradefylline MB-204 Parkinson’s Alzheimer’s & Depression Composition of Matter Patent Filed March 2020 www.marvelbiotechnology.com 10
Slide 11: Pipeline
Pipeline Target Preclinical Discovery Clinical Validation Testing MB-204 Depression & Alzheimer Disease MB-431 Depression Clinical Phase 1 Trials to Commence in Q3 2023 www.marvelbiotechnology.com 11
Slide 12: Lead Asset MB-204: Clinic Bound and Target Alzheimer's Valuations
Lead Asset MB-204: Clinic Bound and Target Alzheimer’s Valuations Alzheimer’s $65M* $117M* Comparables $141M-$169M* $68M* $250M* $83M* Greater than 70% of Phase 1 pharma deals are done Pre-Clinical done Toxicology Phase 1 before Phase 2 in w/efficacy neuroscience space $5M CAD* Marvel Milestones Q1
Slide 13: MB-204 A2a Receptor Antagonist – Substantive External Science
MB-204 A2a Receptor Antagonist – Substantive External Science Successfully Redeveloped Drugs A2a Receptor - Proven Target for Alzheimer’s and Depression 13
Slide 14: MB-204 vs Istradefylline
MB-204 vs Istradefylline Binds to the A2a Longer Lasting in Higher Reduction Lower Anxiety Receptor the body in Depression Symptoms Symptoms MB-204 Istradefylline *Refer to Appendix for Details/Data www.marvelbiotechnology.com 14
Slide 15: MB-204 Potential Near Term Value Creation Events
MB-204 Potential Near Term Value Creation Events Q3:2022 Q1:2023 H2:2023 Begin rat and dog GLP Pilot Phase ½ clinical trial Begin cGMP run of MB-204 results of MB-204 includes for clinic toxicology studies placebo and efficacy Begin Design of Phase 1 endpoints MTD studies Clinical Trials Accelerate
Slide 16: Accelerated FDA Phase I Timeline
Accelerated FDA Phase I Timeline Successfully Redeveloped Drugs • MB-204 has an immediate effect on memory, depression and attention/motivation and does not require more than one dose to collect the needed data • The administered tests for MB-204 provide results in less than one hour • Significantly
Slide 17: Key Takeaways
Key Takeaways Successfully Redeveloped Drugs • First-in-Class drug for two big diseases with TAM of over $40B and growing • Significant internal and external science supporting our approach • Comparable Company, ProMIS Neurosciences (PMN.T) is valued at $70 million at similar toxicology stage VS Cur
Slide 18: Corporate Information
Corporate Information Stock Information: • Ticker: MRVL.V • Shares outstanding: 39,786,231 • Insider Ownership: 13,375,098 (33.6%) • Warrant coverage: 7,200,000 • Stock options granted: 3,350,000 Financial Information: • Cash: $1.24 million (February 28, 2023) • Burn rate (estimated): $82,000 per mo
Slide 19: Management
Management J. Roderick Matheson Dr. Mark Williams Harry Nijjar - CPA, CMA Chief Executive Officer and Director President, Chief Science Officer and Director Chief Financial Officer Mr. Matheson has spent nearly 40 years of his career in the investment and Dr. Williams is Chief Scientific Officer of
Slide 20: Board of Directors
Board of Directors Neil A. Johnson - Director Mr. Johnson has over 30 years of experience in investment banking, merchant banking and research analysis in both the Canadian and UK capital markets. Mr. Johnson is presently, and has been since June 2015, Executive Director and Chief Executive Officer
Slide 21: Scientific Advisory Board
Scientific Advisory Board Dr. David Blum Dr. Blum adds crucial depth to the scientific board for his highly relevant research in the A2A receptor antagonists in cognition, brain lesions, and tau pathology for applications in Alzheimer's Disease (AD). Dr. Blum is a Senior Investigator and a Research
Slide 22: MRVL - TSXV Contact
Rod Matheson Dr. Mark Williams rod@marvelbiosciences.com mark@marvelbiosciences.com 403-770-2468 431-777-7759 MRVL - TSXV 22
Slide 23: Appendix
Appendix www.marvelbiotechnology.com
Slide 24: Redevelopment of Istradefylline to MB-204 – Effective & Longer Lasting
Redevelopment of Istradefylline to MB-204 – Effective & Longer Lasting In Vitro IC50 Oral Pharmacokinetics Forced Swim Test 200 150 Istradefylline MB-204 Time Immobile (2-6 min) ** ** 100 **** 50 0 l p k) p k) pk) tr o C on .5 m (5 m 0m 0 4 (2 -204 2 0 4 (1 -2 B - MB M MB 67 nM 75 nM MB-204 Targets
Slide 25: Redevelopment of Istradefylline to MB-204: Depression
Redevelopment of Istradefylline to MB-204: Depression Latency to Immobility 200 Time Immobile (2-6 min) 200 150 Time Immobile (sec) 150 Time (sec) 100 100 50 50 0 0 Control MB-204 Istradefylline Control MB-204 Istradefylline MB-204 Exhibits Higher Anti-Depressive Activity vs Istradefylline www.marve
Slide 26: Redevelopment of Istradefylline to MB-204: Risky Behaviour Study
Redevelopment of Istradefylline to MB-204: Risky Behaviour Study Risk Behaviour - First 5 Minutes Risk Behaviour - First 10 Minutes Risk Behaviour Longest Single Duration 30 50 5 25 4 20 Mean Mean Mean 3 15 25 2 10 5 1 0 0 0 Placebo MB-204 Istradefylline Placebo MB-204 Istradefylline Placebo MB-204
Slide 27: Redevelopment of Istradefylline to MB-204: Anxiety
Redevelopment of Istradefylline to MB-204: Anxiety 0.8 USV - Number of Calls 0.005 USV- Duration 0.7 0.005 0.6 0.004 Mean 0.5 0.004 Mean 0.003 0.4 0.003 0.3 0.002 0.2 0.002 0.001 0.1 0.001 0 0.000 Placebo MB-204 Istradefylline Placebo MB-204 Istradefylline MB-204 treatment increases frequency and du
Slide 28: Phase 1 Single Ascending Dose (SAD) Design for Efficacy
Phase 1 Single Ascending Dose (SAD) Design for Efficacy: Q3/Q4 2023 Computer administered Efficacy Tests: Successfully Redeveloped Drugs Memory • 24h Consolidation test (Nature Neuroscience 2014, n=35/38 HV) ADHD • Attention/Vigilance: Connor’s CPT-2 (n=69 HV, 12/4 ADHD) • Impulsivity: stop-signal r
Slide 29: Phase 1 SAD Design: Dosing Regimen
Phase 1 Single Ascending Dose (SAD) Design for Efficacy: Q3/Q4 2023 Dosing Regiment Successfully Quantitative Redeveloped Computer Drugs Tests Based Dose 1. (4placebo/12active) Dose 2 (4placebo/12active) 24 hour memory consolidation Dose 3 (4placebo/12active) CPT-2 Dose x (4placebo/12active) Stop Si
Marvel Biosciences — Investor Presentation (May 2023) on 6ix